VivoSeq
Oncology

Urinary Bladder Neoplasms

5

Pipeline Programs↗

3

Active Trials↗

5

Companies Involved↗

Urinary Bladder Neoplasms is an early-stage landscape with 5 programs across 5 companies. The most active players are Janssen Pharmaceutical K.K., Merck & Co., Johnson & Johnson. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

J

Janssen Pharmaceutical K.K.

1 program

Phase 1Merck & Co. logo

Merck & Co.

2 programs

Phase 2Johnson & Johnson logo

Johnson & Johnson

3 programs

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3Eli Lilly logo

Eli Lilly

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

3 of 4 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody125%

Small molecule leads; the ring shows all 4 classified programs, each share of the total. Modality classified for 86% of 7 pipeline programs.

Analysis

Trial Status

5

clinical trials

Active, not recruiting2 · 40%
Recruiting1 · 20%
Available1 · 20%
Completed1 · 20%

Clinical Trials

Trial Activity

A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT04658862·518 enrolled
A Phase 1 Study to Evaluate the Tolerability, Safety, and Pharmacokinetics of TAR-210 in Japanese Participants With Bladder Cancer and Selected FGFR Mutations or Fusions
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT05567185·5 enrolled
A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)
Recruiting·Merck & Co. logoMerck & Co.·Phase 2·NCT06833073·308 enrolled
Expanded Access for Vepugratinib in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors
Available·Eli Lilly logoEli Lilly·N/A·NCT07675057
A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 2·NCT04919512·163 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)